Patents Assigned to Rosetta Genomics Ltd
  • Patent number: 8680067
    Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: March 25, 2014
    Assignees: Regulus Therapeutics, Inc., Rosetta Genomics Ltd
    Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
  • Patent number: 7687616
    Abstract: The present invention describes a novel approach whereby small molecules may be used to modulate activity of microRNA and GAM oligonucleotides. This mode of therapy allows inter alia up regulation of a disease-related target gene of novel GAM oligonucleotides of the present invention, by countering the activity of a GAM oligonucleotides which naturally inhibits expression of that target gene. Nucleic acid molecules are provided respectively encoding 122,764 GAM oligonucleotides and their respective precursors, and 18602 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: March 30, 2010
    Assignee: Rosetta Genomics Ltd
    Inventors: Itzhak Bentwich, Amir Avniel
  • Patent number: 7642348
    Abstract: Described herein are novel polynucleotides associated with prostate cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of prostate cancer. Also described herein are methods that can be used to identify modulators of the disease-associated polynucleotides. Also described herein are methods and compositions for linear amplification and labeling of a targeted nucleic acid. The amplified targeted molecules may be used in hybridization techniques like Luminex and Microarray analysis.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: January 5, 2010
    Assignee: Rosetta Genomics Ltd
    Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
  • Patent number: 7592441
    Abstract: Described herein are novel polynucleotides associated with liver cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of liver cancer. Also described herein are methods that can be used to identify modulators of the disease-associated polynucleotides. Also described herein are methods and compositions for linear amplification and labeling of a targeted nucleic acid. The amplified targeted molecules may be used in hybridization techniques like Luminex and Microarray analysis.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: September 22, 2009
    Assignee: Rosetta Genomics Ltd
    Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
  • Patent number: 7217807
    Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “genomic record” or “GR” genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: May 15, 2007
    Assignee: Rosetta Genomics Ltd
    Inventor: Itzhak Bentwich